The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura

Blood. 2015 Mar 5;125(10):1526-31. doi: 10.1182/blood-2014-10-559211. Epub 2015 Jan 8.

Authors

Wendy Lim¹, Sara K Vesely², James N George²

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, ON, Canada; and.
² Department of Biostatistics and Epidemiology, College of Public Health, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Review

MeSH terms

ADAM Proteins / blood
ADAM Proteins / deficiency
ADAMTS13 Protein
Adrenal Cortex Hormones / therapeutic use
Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Combined Modality Therapy
Evidence-Based Medicine
Female
Humans
Plasma Exchange
Platelet Count
Purpura, Thrombotic Thrombocytopenic / blood
Purpura, Thrombotic Thrombocytopenic / therapy*
Recurrence
Rituximab

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Murine-Derived
Rituximab
ADAM Proteins
ADAMTS13 Protein
ADAMTS13 protein, human

Supplementary concepts

Thrombotic thrombocytopenic purpura, acquired

Grants and funding